Novartis scatters its VC seeds widely by leading rounds across a variety of therapy areas, although oncology still represents a big share of its funding activity.
{iframe}http://www.evaluate.com/vantage/articles/data-insights/other-data/rest-biopharma-investors-corporate-vcs-love-oncology{/iframe}